6-substituted-3-phenylisoindorin-1-one as a selective CBL-B inhibitor against C-CBL

6-substituted-3-phenylisoindolin-1-one compounds selectively inhibit Cbl-b, addressing the challenge of specificity in cancer immunotherapy by enhancing T cell-mediated antitumor immunity and natural killer cell activity.

JP2026517862APending Publication Date: 2026-06-02GENENTECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
GENENTECH INC
Filing Date
2024-05-09
Publication Date
2026-06-02

Smart Images

  • Figure 2026517862000001_ABST
    Figure 2026517862000001_ABST
Patent Text Reader

Abstract

Equation (I) or (II) This compound, TIFF2026517862000112.tif80170, is suitable for treating cancers that are susceptible to Cbl-B inhibition.
Need to check novelty before this filing date? Find Prior Art